Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets.
The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial.
Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 24 | -0.94 Increased by +5.05% | -0.89 Decreased by -5.62% |
| Aug 7, 24 | -0.81 Increased by +11.96% | -0.77 Decreased by -5.19% |
| May 8, 24 | -0.70 Increased by +2.78% | -0.75 Increased by +6.67% |
| Feb 26, 24 | -1.14 Decreased by -80.95% | -0.88 Decreased by -29.55% |
| Nov 6, 23 | -0.99 Decreased by -13.79% | -1.01 Increased by +1.98% |
| Aug 8, 23 | -0.92 Decreased by -12.20% | -0.82 Decreased by -12.20% |
| May 8, 23 | -0.72 Increased by +7.69% | -0.81 Increased by +11.11% |
| Feb 27, 23 | -0.63 Increased by +11.27% | -0.82 Increased by +23.17% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by N/A% | -156.29 M Decreased by -44.13% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -133.23 M Decreased by -35.54% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -116.00 M Decreased by -98.28% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 742.00 K Decreased by -95.16% | -161.54 M Decreased by -185.87% | Decreased by -21.77 K% Decreased by -5.81 K% |
| Sep 30, 23 | 0.00 Decreased by -100.00% | -108.43 M Decreased by -47.87% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 3.82 M Decreased by -58.05% | -98.30 M Decreased by -62.87% | Decreased by -2.57 K% Decreased by -288.26% |
| Mar 31, 23 | 7.01 M Decreased by -7.44% | -58.51 M Decreased by -2.02% | Decreased by -834.13% Decreased by -10.23% |
| Dec 31, 22 | 15.33 M Increased by +62.05% | -56.51 M Decreased by -7.27% | Decreased by -368.60% Increased by +33.80% |